紫鑫藥業(002118.SZ):公司控股股東將變更為國藥兆祥
格隆匯10月20日丨紫鑫藥業(002118.SZ)公佈,2021年10月19日,公司控股股東敦化市康平投資有限責任公司(“康平投資”)與國藥兆祥(長春)醫藥有限公司(“國藥兆祥”)簽署了《表決權委託協議》,根據協議,康平投資將其持有的公司2.85億股,佔股本總額22.28%的股份(其中41,751,300股,佔股本總額3.26%的股份,已經被司法拍賣,尚未辦理過户登記,股份數以行權時實際持有股份數為準)對應的投票表決權,包括但不限於股東提案權、股東表決權等相關權利委託給國藥兆祥行使。
國藥兆祥同意代為行使上述股份的表決權。本次變更後郭春生不再為公司實際控制人;本次表決權被委託方國藥兆祥(長春)醫藥有限公司為國藥藥材股份有限公司全資子公司,因目前國藥藥材股份有限公司處在股份變更階段,公司實際控制人待國藥藥材股份有限公司股份變更後確認。國藥兆祥將成為公司的控股股東,取得公司控制權。
同日,公司控股股東康平投資的股東郭榮、劉瑞寶、仲桂蘭分別與國藥兆祥簽署了《表決權委託協議》,根據協議,郭榮將其持有的康平投資佔股本總額29.5382%的股份;劉瑞寶將其持有的康平投資佔股本總額6.3515%的股份;仲桂蘭將其持有的康平投資佔股本總額24.2603%的股份對應的投票表決權,包括但不限於股東提案權、股東表決權等相關權利委託給國藥兆祥行使。
國藥兆祥同意代為行使上述股份的表決權。國藥兆祥成為康平投資的控股股東。
公司及原控股股東、實際控制人面臨債務危機導致的經營困境,此次引入具備國有資產及產業背景的控股股東國藥兆祥,有利於在資金、資源上給予上市公司有效支持,優化公司股東結構,降低公司負債水平,同時控股股東的中醫藥產業背景有助於上市公司聚焦主業,全面提升上市公司的持續經營能力,推動公司持續發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.